## EMN: Eastman Chemical Company - XLB: Basic Materials

### Executive Summary

No thesis match: MRS_10 -0.8% below STRENGTH zone (3.0-6.0%); PEG 3.13 fails VALUE criteria (<1.0). Stock is in no-man's land without clear edge.

- **Horizon:** N/A - no position
- **Risk Profile:** N/A - avoiding
- **Stop Type:** Fixed 2xATR ($57.37)
- **If Wrong:** N/A - wait for clearer setup
- **Invalidation:** MRS_10 falling below -5% or breaking key support

### News

- **Articles:** 3
- **Sentiment:** Bullish (Bullish: 2, Bearish: 0)

**1. Shareholders to receive increased dividend as Eastman (EMN) extends 16-year streak**
- Source: MSN | 20251210T021719 | Bullish | Relevance: 99%
- Eastman (EMN) has announced an increased dividend for shareholders, continuing its 16-year streak of dividend growth. This move signals the company's commitment to returning value to investors through consistent dividend payments.

**2. Shareholders to Receive Increased Dividend as Eastman (EMN) Extends 16-Year Streak**
- Source: Insider Monkey | 20251209T204200 | Bullish | Relevance: 98%
-  Eastman Chemical Company (NYSE: EMN) has announced a 1.2% increase in its quarterly dividend to $0.84 per share, marking its 16th consecutive year of dividend growth. The company, which is prioritizing cash generation and cost reduction, aims to deliver continued value to shareholders. EMN generated $402 million in operating cash flow in Q3 2025 and distributed $146 million to shareholders through dividends and share repurchases.

**3. Zacks Industry Outlook Highlights Air Products and Chemicals, Albemarle and Avient**
- Source: TradingView | 20251209T100819 | Neutral | Relevance: 56%
- The Zacks Chemicals Diversified industry faces headwinds from subdued demand in key markets like consumer durables and building & construction, exacerbated by inflation in Europe and a slow recovery in China. Companies like Air Products and Chemicals, Albemarle, and Avient are implementing cost reductions and price hikes to navigate these challenges. Despite a bleak industry outlook, these three companies are highlighted for their strategic initiatives and growth prospects.

### Analyst Activity

**Target Signal:** NEUTRAL (Raises: 0, Lowers: 1)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-11-11 | Evercore ISI Gr | $70 | $75 | -7% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-11-11 | Evercore ISI Gr | main | In-Line |

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **NET_BUYING** |
| Buys | 11 ($0.08M) |
| Sells | 0 ($0.00M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 46.1% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 4 / 6 |

**Top Holders:**
- Vanguard Group Inc: 12.6% (-2.2%)
- Blackrock Inc.: 7.0% (+0.9%)
- State Street Corpora: 5.0% (+24.3%)
- Capital Research Glo: 3.7% (-1.0%)
- Dimensional Fund Adv: 3.5% (+14.4%)

### Key Risks

1. Valuation risk: PEG 3.1x with declining EPS estimates leaves no margin for error.
2. Long-term trend broken: trading 16.4% below SMA200.
3. Market regime shift could impact momentum names disproportionately.

### Catalysts

- AI/machine learning initiatives could drive multiple expansion if executed.
- Broader market risk-on sentiment could lift quality names.

### Fundamentals

PEG ratio 3.13 signals overvaluation risk, limited margin of safety. Forward P/E 9.8x attractive for 15% earnings growth. Analyst sentiment negative (1 target cuts vs 0 raises). Institutional flow bullish (4 buying vs 6 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $7.0B |
| Beta | 1.25 |
| 52W Range | $56.11 - $103.82 |
| Short Interest | 4.2% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 3.13 |
| Forward P/E | 9.8 |
| Current P/E | 11.2 |
| YoY Growth | 14.6% |
| EPS Direction | FALLING |

### Technicals

MRS_10 deteriorating from 0.3% to -0.8% (-1.1% in 5 days), indicating relative weakness vs NASDAQ. Below STRENGTH zone by 3.8pp (needs >3.0% for momentum thesis). MRS_5 turning positive (0.0%) - potential reversal signal. Below SMA200 (0.84x), long-term trend not supportive. RSI neutral at 52.

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_10 | -0.80% (CS: 50) | Neutral |
| RSI_14 | 51.8 | Neutral |
| MACD Histogram | 0.22 | Bullish |
| vs SMA20 | 1.017x | Above |
| vs SMA50 | 1.004x | Above |
| vs SMA200 | 0.836x | Below |

### Decision

- **Verdict:** AVOID
- **Thesis:** NEUTRAL

### Trade Setup

- **Entry:** $61.21
- **Stop Loss:** $57.37 (6.3% risk)
- **Target:** $65.05 (R:R method)
- **Risk/Reward:** 1.00:1
- **Target Reasoning:** NEUTRAL thesis targets 1.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 130
- **Position Value:** $7,957.30
- **Portfolio %:** 7.96%
- **Risk Dollars:** $500.00
- **Risk Per Trade:** 0.50%
- **Modifiers:** L1 100% | L2 50% | Combined 0.50x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 1.00x |
| L2 Sector | AVOID (Zone C) | 0.50x |

*NORMAL regime with moderate risk appetite. VIX remains in the mid-range, breadth is moderate, and yield curve is flat but not invertedâ€”indicating standard late-cycle conditions. Upbeat earnings and positive tech momentum are offset by cautious guidance in consumer sectors, suggesting selective positioning is favored.*

### Earnings

**Next:** 2026-01-29 (Est: $0.81)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $1.17 | $1.14 | -2.2% |
| 2025Q2 | $1.75 | $1.60 | -8.7% |
| 2025Q1 | $1.89 | $1.91 | +1.2% |
| 2024Q4 | $1.57 | $1.87 | +18.9% |

---
*RULE-based L3 | 2026-01-06 16:37 | MRS_10*